
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia is well positioned because the October 2026 settlement with United Therapeutics removes a major legal overhang, preserves full YUTREPIA economics in PAH, and lets management concentrate on a clearer franchise strategy. Commercially, YUTREPIA has shown durable traction with five straight quarters of sales growth, 3Q26 net product sales up 31% QoQ to about $222.7 million, more than 70% of September referrals carrying a PAH diagnosis, and cumulative patient starts estimated at roughly 6,000–6,400 by the end of October. Fundamentally, the company also has multiple catalysts beyond the launch, including a Phase 4 program beginning in 4Q26, LTI-403 primary completion expected in 2Q27, and L606 supporting a potential NDA submission in 2029, while 3Q26 cash of about $396 million and a reported non-GAAP adjusted EBITDA of $140.5 million provide financial flexibility.
Bears say
Liquidia is a difficult commercial story because Yutrepia enters a pulmonary arterial hypertension market already dominated by established players such as United Therapeutics and Actelion, with Tyvaso and Tyvaso DPI posing direct, well-entrenched competitive threats. The company must also fund the commercialization of Yutrepia and L606, if approved, which implies significant and rising operating expenses before any meaningful scale is achieved. That funding burden creates a high likelihood of substantial capital needs and potentially dilutive financings, making the equity structurally unattractive on a fundamental basis.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Liquidia Technologies Inc (LQDA) Forecast
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares